Analysts Set Hikma Pharmaceuticals PLC (LON:HIK) PT at GBX 2,085.83

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have covered the stock in the last year is GBX 2,085.83.

Several equities research analysts recently weighed in on HIK shares. Jefferies Financial Group upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Berenberg Bank lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Finally, Citigroup upped their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday, August 12th.

Hikma Pharmaceuticals Trading Up 0.7%

Shares of LON:HIK opened at GBX 1,507.99 on Friday. The company has a market capitalization of £3.12 billion, a P/E ratio of 8.57, a P/E/G ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a 1 year low of GBX 1,187 and a 1 year high of GBX 1,865. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The business’s 50 day simple moving average is GBX 1,599.55 and its 200 day simple moving average is GBX 1,461.39.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Tobias Hestler acquired 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average price of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is currently owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.